Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Two-Part, Fixed-Sequence Crossover Study to Evaluate the Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Male Subjects

Next Previous
Search
Trial Profile

A Phase 1, Open-Label, Two-Part, Fixed-Sequence Crossover Study to Evaluate the Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Male Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lenalidomide (Primary) ; Diphenhydramine; Quinidine; Temsirolimus
  • Indications Acute myeloid leukaemia; Allergic rhinitis; Amyotrophic lateral sclerosis; Breast cancer; Chronic lymphocytic leukaemia; CNS cancer; Colorectal cancer; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Eye neoplasms; Follicular lymphoma; Glioblastoma; Head and neck cancer; Heart failure; Hodgkin's disease; Inflammation; Liver cancer; Malignant melanoma; Mantle-cell lymphoma; Multiple myeloma; Multiple sclerosis; Myelodysplastic syndromes; Myelofibrosis; Non-Hodgkin's lymphoma; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer; Renal cancer; Rheumatoid arthritis; Soft tissue sarcoma; Solid tumours
  • Focus Pharmacokinetics

Most Recent Events

  • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 16 Nov 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top